Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P(1) Receptor Modulator in Clinical Trials

[Image: see text] Clinical validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within h...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:ACS Med Chem Lett
Główni autorzy: Dhar, T. G. Murali, Xiao, Hai-Yun, Xie, Jenny, Lehman-McKeeman, Lois D., Wu, Dauh-Rurng, Dabros, Marta, Yang, Xiaoxia, Taylor, Tracy L., Zhou, Xia D., Heimrich, Elizabeth M., Thomas, Rochelle, McIntyre, Kim W., Warrack, Bethanne, Shi, Hong, Levesque, Paul C., Zhu, Jia L., Hennan, James, Balimane, Praveen, Yang, Zheng, Marino, Anthony M., Cornelius, Georgia, D’Arienzo, Celia J., Mathur, Arvind, Shen, Ding Ren, Cvijic, Mary Ellen, Salter-Cid, Luisa, Barrish, Joel C., Carter, Percy H., Dyckman, Alaric J.
Format: Artigo
Język:Inglês
Wydane: American Chemical Society 2016
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4789672/
https://ncbi.nlm.nih.gov/pubmed/26985316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00448
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy